Alumis reported positive Phase III Onward1 and Onward2 results for its oral TYK2 inhibitor envudeucitinib in psoriasis, data that position the pill among leading oral therapies for the disease. The company followed the readout by planning a $175 million follow‑on financing to support late‑stage development. Topline efficacy from the Phase III program showed clinically meaningful skin clearance versus comparator benchmarks and safety consistent with the TYK2 class. Alumis said the results intensify competition among oral TYK2 candidates from other developers and could reshape market dynamics for non‑injectable psoriasis treatments. Alumis intends to use the new capital to advance regulatory filings and commercial planning; analysts noted head‑to‑head positioning against other TYK2 and oral immunomodulators will hinge on durability, safety signals and labeling differentiation.